WASHINGTON, Jan. 13, 2026 — NGP VAN, the leading technology provider for Democratic and progressive campaigns and organizations, today announced the creation of its first-ever API and Data Products Team, alongside a seven-figure investment to modernize and expand the NGP VAN’s APIs. This new team will focus exclusively on strengthening the infrastructure that powers integrations across the progressive technology ecosystem.

This team – comprised entirely of union roles – will be dedicated to expanding API capabilities and delivering new data products in direct response to feedback from customers and integration partners, who increasingly rely on NGP VAN’s APIs as foundational scaffolding for building powerful tools and workflows.

“Our customers and partners have been clear: NGP VAN’s APIs are mission critical to modern organizing,” said Chelsea Peterson Thompson, General Manager of NGP VAN. “This investment reflects our responsibility to the ecosystem: focused teams, faster shipping, and an API engineered to scale with the future of campaigns and advocacy.” 

These new investments underscore the organization’s expanding role not only in supporting campaigns, parties, PACs, and progressive organizations directly, but also the wide range of third-party tools they rely on, including mobile messaging, digital advertising, analytics, and insights platforms.

The new API and Data Products Team also builds directly on NGP VAN’s Partner Program, by investing in dedicated API development, NGP VAN aims to deepen collaboration with partners and deliver world-class, reliable integrations that help Democratic and progressive campaigns move faster and smarter.

The announcement follows investments made in 2024 to expand API rate limits for all customers and vendors, enabling faster data synchronization while maintaining platform integrity.

Most recently, NGP VAN shipped several API enhancements to its Membership endpoints, including the ability to:

• Expose Membership Type via the Bulk Import method
• Support Member Type and Affiliates Custom Fields through Bulk Import
• Rename Custom Field values via a PUT method
• Expose the Apply Contributions mapping type

These updates reflect the company’s ongoing commitment to making its APIs more flexible, powerful, and responsive to real-world cases.

NGP VAN will be hiring three software engineers to form the core of the API and Data Products Team. As with all NGP VAN roles, those with experience building and scaling APIs are encouraged to apply at ngpvan.com/careers/. This team will be supported by continued investment in third-party platform modernization partners, as well as NGP VAN’s broader engineering organization, which has recently completed several API-focused initiatives. NGP VAN is a unionized employer.

About NGP VAN
NGP VAN is the winningest technology platform in the history of democratic and progressive causes, working tirelessly to innovate and advance the technology our clients rely on to bolster our democracy. We help power the trailblazers, campaigners, and advocates fighting up and down the ticket for equality, racial justice, reproductive freedom, democracy, climate reform, and more— including the national Democratic committees and progressive organizations, thousands of Democratic campaigns, hundreds of labor unions, advocacy organizations, progressive and non-partisan PACs, and other organizations.

Press Contact:
Simone Hassan-Bey
NGP VAN
[email protected]

SOURCE NGP VAN

LONDON, Jan. 13, 2026 — Dirk-Jan Vorgers and Ekaterina Kupriyanova, who formerly led the European office of Harvey & Company, have launched Aquisor, a European M&A buy-side advisory firm, focused on partnering with private equity firms to accelerate portfolio growth through platform and add-on acquisitions. Aquisor is backed by an experienced group of entrepreneurs and private equity professionals who have prior experience in the field.

Aquisor offers a fully dedicated service of pre-deal market mapping and buy-side deal origination, combining research-led target identification with direct outreach and structured project management to help clients generate more acquisition opportunities and better deals. Built on deep M&A and private equity experience, Aquisor leverages tech-enabled research and localised outreach in native languages with a disciplined workflow, designed to progress opportunities from initial engagement to closing of the deal.

Ekaterina Kupriyanova, COO at Aquisor, said: “Great M&A sourcing is, above all, building trust with business owners. We earn it through a thoughtful, owner-first approach: understanding the market and their operations, testing strategic fit with our client’s thesis, and managing a well-run process. With proprietary research tools and our multilingual team, we are establishing Aquisor as the leading European buy-side partner our clients can rely on.”

Dirk-Jan Vorgers, CEO, added: “Unlike traditional M&A sourcing firms, Aquisor operates as an extension of its clients’ M&A capabilities, enabling them to focus on what creates most value for them and remaining engaged throughout the entire process..”

Media Enquiries: 
Please contact: [email protected]

About Aquisor
Aquisor is a European M&A buy-side advisory firm focused on pre-deal market mapping and buy-side deal origination for private equity firms. Combining technology-enabled research, multilingual direct outreach, and deep transaction experience, Aquisor delivers high-quality acquisition opportunities and accelerates portfolio growth through platform and add-on acquisitions.

For more information, visit: Aquisor.

Photo – https://mma.prnewswire.com/media/2858390/Aquisor_Logo.jpg

SOURCE Aquisor

LAS VEGAS, Jan. 13, 2026 — BookAI, the pioneer in cross-language Knowledge Computing, announced today the official opening of its Seed Round financing via SAFE notes. The announcement comes immediately after a breakthrough showcase at CES 2026, where BookAI validated its B2B2C model through strategic integrations with AIoT hardware, moving beyond concepts to commercial scalability.

From “Concept” to “Contract”: The Commercial Moat

Unlike many early-stage GenAI startups, BookAI demonstrated market-ready infrastructure capable of handling complex copyright compliance—a critical demand from global IP holders.

“We proved at CES that BookAI is not just a tool, but the ‘Intel Inside’ for the global knowledge economy,” said Kun-Lin Hsieh, Founder and CEO of BookAI. “By embedding our Nabu and Miva engines into third-party devices—like our new partnership with Korean smart lamp maker CN Inc.—we have unlocked a scalable path to transform static content into IntelliBooks and monetize them across borders instantly.”

Dual-Engine Growth Validation:

• The Hardware Engine (CES 2026): Confirmed B2B2C traction. BookAI’s technology successfully powered the DAL:BIT smart lamp, allowing English speakers to interact with Traditional Chinese content in real-time. This “Knowledge-as-a-Service” model attracted immediate inquiries from Japanese venture capital (focused on IP expansion) and Silicon Valley investors (focused on scalable AI infra).
• The Content Engine (Frankfurt Book Fair): Confirmed B2B demand. The Nabu platform was adopted by over 230 publishers from 15 countries, with 62% of traction coming from Western markets, proving a solved pain point in the $600B copyright trading market.

Investment Opportunity: The Seed Round

To capitalize on this global momentum, BookAI has initiated its Seed Round. The raise is structured via SAFE (Simple Agreement for Future Equity) to efficiently onboard strategic partners who align with BookAI’s vision of a borderless knowledge ecosystem.

About BookAI

BookAI is an AI Knowledge Computing Platform transforming how the world accesses information. Backed by Taiwan Tech Arena (TTA), BookAI connects global publishers with AIoT devices, turning static text into IntelliBooks—liquid, interactive, and tradable assets.

Media & Investor Contact: BookAI PR Team Email: [email protected], LinkedIn: https://www.linkedin.com/company/bookai2024

SOURCE BookAI

SHENZHEN, China, Jan. 12, 2026 — X Square Robot, a pioneer in general purpose embodied AI, announced on January 12 the completion of its Series A++ funding round, raising about US$140 million (RMB 1 billion). The funding attracted world-class investors, including ByteDance and HongShan, along with several other strategic Chinese partners.

With leading tech companies such as Alibaba Group and Meituan already backing it from previous rounds, X Square Robot has demonstrated compelling model capabilities and product potential that continue to attract investor confidence.

“We’re honored to have the strong endorsement of our world-class strategic investors,” said WANG Qian, founder and CEO of X Square Robot. “At X Square, we believe the key to enabling robots to truly master real-world tasks lies in the ‘robot brain’—a foundation model for the physical world that parallels virtual LLMs to shatter generalization bottlenecks. This investment underscores shared confidence in our role as a catalyst for technological progress and will accelerate our expansion into high-value applications.”

WALL-A: Integrating VLA with World Models for Continuous Real-World Evolution

Founded in December 2023, X Square Robot is a trailblazer in developing general-purpose end-to-end embodied AI foundation models in China. The company’s in-house developed VLA model, WALL-A, pioneered a system paradigm that deeply integrates VLA with World Models, ranking among the world’s most advanced systems. By using World Models to predict actions and causal inference to understand feedback, the model significantly enhances the zero-shot generalization capabilities of robots performing mobile manipulation tasks in unstructured environments.

Simultaneously, large-scale real-robot reinforcement learning (RL) allows the foundation model to learn through physical interaction. This data-driven approach enables the robot to autonomously refine its skills and perform complex tasks in real-world environments.

Alongside the development of WALL‑A, X  Square Robot introduced WALL‑OSS in September 2025, an open‑source version of its model family designed to democratize embodied intelligence and accelerate community‑driven innovation.

“The next phase of competition in embodied intelligence is essentially a battle of foundation models built on data closed-loops and their capacity for model evolution,” noted Mr. Wang.

To win this race, X Square Robot is also adhering to a closed-loop iteration of hardware, data, and models. As the first company in China to scale up real-world data resources, it has developed advanced data capture tools—including teleoperation, exoskeletons, and Universal Manipulation Interface (UMI). The company has also established a model-driven data pipeline that generates high-quality data at scale. By using the foundation model to provide feedback on hardware design and data processing, X Square Robot is improving acquisition efficiency and model performance, creating a self-reinforcing “flywheel”.

A First in Robotics: Fully Autonomous Food Delivery Using Foundation Models

This end-to-end adaptability is proof that embodied AI has moved into practical, real-world deployment. A landmark breakthrough was recently demonstrated in autonomous food delivery, powered by Wall-A, where the Quanta X1, X Square Robot’s wheeled bimanual robot, successfully navigated indoor and outdoor tasks to complete a delivery in an open environment.

During the mission, Quanta X1 handled challenges such as strong winds, deformed packaging, and visual occlusions. Much like a human, the robot used the model’s causal inference to “fill in the blanks” when objects were partially hidden. When encountering operational stalls or friction, the robot autonomously self-corrects and completes the task loop without any human intervention.

This capacity is also demonstrated in complex logistics; facing piles of parcels, the robot utilizes zero-shot generalization to identify irregular items. Notably, the model’s evolution has unlocked the potential of high DoF (degree of freedom) dexterous hands, mastering human-like skills from tool use to precise card dealing—successfully conquering the “last centimeter” of precision manipulation.

From Full-Stack R&D to Multi-Scenario Deployment

Driven by model and data requirements, X Square Robot has deeply defined its hardware architecture, releasing two high-performance robots: Quanta X1 and the Quanta X2, a wheeled humanoid robot. Meanwhile, X Square Robot also uses in-house developed core components—including robotic arms, joint modules, and controllers—establishing a solid foundation for mass production and commercial scale.

“X Square Robot continues to iterate across our three core pillars: models, data pipelines, and hardware,” said Wang. “By leveraging our technical depth and full-stack R&D, we consistently push the boundaries of robot performance.”

Today, X Square Robot’s solutions are driving “a new era where embodied intelligence powers every layer of productivity.” Its technologies are increasingly deployed across key industry verticals—from advanced manufacturing and autonomous logistics to senior healthcare services.

Email: [email protected] 

SOURCE X Square Robot

BELFAST, Northern Ireland  , Jan. 12, 2026 — PulseAI, a rapidly emerging leader in AI-enabled cardiac diagnostics, today announced the closing of its seed funding round, led by Innovation Ulster Limited, with participation from The Mortara Group and The Francis Crick Institute. The investment will enable PulseAI to scale deployment of its AI-ECG technology and advance its pathway through US FDA 510(k) clearance.

Over 300 million electrocardiograms (ECGs) are performed annually worldwide. However, despite the critical importance of the ECG as a frontline diagnostic tool, its interpretation remains highly dependent on specialist training and manual analysis. This often leads to delays, diagnostic variability, and missed opportunities for early intervention. PulseAI’s AI-ECG platform is designed to address this challenge directly by delivering high-performance clinical decision support in both primary and acute care settings.

As part of the round, Dr. Justin Mortara, an experienced innovator in ECG technologies and former CEO of Mortara Instruments, will join PulseAI as Chair of the Board, strengthening the company’s strategic alignment with global leaders in cardiac monitoring, diagnostics, and hospital systems.

PulseAI’s technology, trained on large-scale ECG datasets and validated in partnership with some of the world’s leading institutions across Europe and the United States, promises to bring the power of AI to one of the most widely used diagnostic tests.

The new investment will accelerate:

• Regulatory advancement, including FDA 510(k), further clinical validation across diverse populations and care settings
• Productisation for enterprise and OEM integration
• Expansion of partnerships with device manufacturers and hospital networks

“This investment marks a pivotal moment for PulseAI as we move into full clinical and regulatory execution,” said Dr Alan Kennedy, Founder and CEO of PulseAI. “Our goal is to deliver advanced ECG technology that can expedite and improve the accuracy of cardiac diagnostics, reducing variability and expanding access to high-quality diagnostics in all areas of healthcare.”

“PulseAI sits at the intersection of clinical rigour, scalable technology, and real market need,” said Justin Mortara, incoming Chair of the Board. “The company is building a platform with the potential to elevate ECG interpretation across the entire care continuum, pairing its AI with traditional medical devices as well as a growing array of consumer wearables. I’m excited to support the team as they move through regulatory milestones to broader industry adoption”

SOURCE PulseAI

NEW YORK, Jan. 12, 2026 — Natixis Corporate & Investment Banking (Natixis CIB) is proud to announce its role as Joint Bookrunner and Joint Lead Arranger in a landmark $281 million project financing for Ruta del Este, concessionaire company formed by ISA Vías (previously Intervial Chile S.A.) to develop the project. This project marks the first concession awarded in Panama under the Public-Private Partnership (PPP) Law of 2019.

The financing will facilitate the execution of the Panamericana del Este road project, a critical infrastructure project that involves the rehabilitation and repaving of an approximately 246-kilometer corridor linking the eastern outskirts of Panama City to the Darien province near the Colombian border. This initiative aligns with Natixis CIB’s commitment to social transportation goals and reinforces its expertise and leadership in the region and sector.

“We are honored to support ISA, ISA Vías, and the Ruta del Este project as it represents a significant milestone as the first-ever PPP concession in Panama,” said Aitor Alava, Head of Infrastructure & Energy Finance Latin America at Natixis CIB. “At Natixis CIB, we are dedicated to partnering with our clients in their efforts to expand into new markets, showcasing our underwriting capabilities in this pioneering financing. The Panamericana del Este, part of Panama’s most vital highway, serves as the primary road link between Panama City and the Guna Yala communities along the coast, as well as the Darien region bordering Colombia. This project is poised to benefit agricultural producers by enhancing their access to demand centers, creating approximately 1,500 direct jobs during construction, and significantly reducing travel time by about 1.5 hours from end to end of the road.”

ISA Vías, a subsidiary of ISA, is recognized as one of the largest operators of road concessions in Latin America, managing over 1,200 kilometers of road infrastructure.

Andres Contreras, Chief Executive Officer (CEO) of ISA Vías, stated, “This operation not only highlights the bank’s confidence in Panama but also showcases ISA Vías´ robust business model, which continues to drive our goal of becoming a leader in road infrastructure across Latin America.”

About Natixis Corporate & Investment Banking
Natixis Corporate & Investment Banking is a leading global financial institution that provides advisory, investment banking, financing, corporate banking and capital markets services to corporations, financial institutions, financial sponsors and sovereign and supranational organizations worldwide.

Our teams of experts in about 30 countries advise clients on their strategic development, helping them to grow and transform their businesses, and maximize their positive impact. Natixis CIB is committed to aligning its financing portfolio with a carbon neutrality path by 2050 while helping its clients reduce the environmental impact of their business.

As part of Groupe BPCE, the second largest banking group in France through the Banque Populaire and Caisse d’Epargne retail networks, Natixis CIB benefits from the Group’s financial strength and solid financial ratings (Standard & Poor’s: A+, Moody’s: A1, Fitch: A+, R&I: A+).

Press contact:
Tara Flanagan, Prosek Partners
Tel: +1 646 818 9022
[email protected]

cib.natixis.com 
https://www.linkedin.com/company/natixis-corporate-investment-banking/
https://www.youtube.com/user/natixisvideos
https://podcast.ausha.co/green-momentum

Our information is certified with blockchain technology.
Check that this press release is genuine at www.wiztrust.com.

SOURCE Natixis

DENVER, Jan. 12, 2026 — Neuramint, the leading AI agent platform empowering developers to build and manage autonomous Web3 workflows, today announced the successful completion of its $5 million seed funding round. The round attracted participation from leading Web3 and AI-focused investment firms, including Maelstrom, Borderless Capital, Selini Capital, Symbolic Capital, Lattice Fund, and Node Capital.

Neuramint enables developers to create intelligent workflows that interact with DeFi protocols, NFT marketplaces, and blockchain networks—all without writing complex smart contract integrations. Through a visual drag-and-drop interface, developers can build, simulate, and deploy autonomous AI agents that coordinate tasks across multiple chains with precision and reliability.

Key differentiators of the Neuramint platform include a visual workflow builder for drag-and-drop agent creation, native multi-chain support across Ethereum, Solana, HyperEVM, and beyond, a production-grade simulation sandbox for safe testing on forked mainnets, gas optimization through intelligent transaction batching, and an agent marketplace for sharing and monetizing workflows.

This seed funding will accelerate platform development, expand Web3-native SDK integrations, and support the upcoming public launch of Neuramint Beta. Proceeds will also drive further integration with major DeFi protocols and blockchain networks, enabling DeFi automation, NFT operations, cross-chain bridging, and DAO governance at scale.

About Neuramint

Neuramint, a Web3 AI company, is at the forefront of the agentic AI revolution, delivering a development platform that empowers developers to automate and manage complex blockchain operations through autonomous AI agents. By combining cutting-edge AI with the flexibility of blockchain, Neuramint is redefining how developers build autonomous agents that interact with decentralized financial ecosystems.

Contact:
Daniel Chan
[email protected]
https://www.neuramint.xyz/

SOURCE NEURAMINT LIMITED

$1 Million NJIEF Investment Matches Edge Medical Ventures Funding to Expand US Commercialization

JERSEY CITY, N.J. and OR YEHUDA, Israel, Jan. 12, 2026 — Synchrony Medical, a respiratory care technology company and creator of the FDA-cleared LibAirty™ airway clearance system, today announced it has secured additional funding through a $1M investment from the New Jersey Innovation Evergreen Fund (NJIEF). Matching an Edge Medical Ventures investment, the funding will be used to accelerate U.S. commercial operations, support continued clinical research and product development, and expand patient access to LibAirty™ through respiratory clinics, hospitals, and homecare networks nationwide.

LibAirty™ is the first FDA-cleared airway clearance system providing guided breathing synchronized with targeted chest compressions to help patients clear their lungs effectively and comfortably through a short daily treatment at home. Regular airway clearance is essential for people living with conditions such as chronic obstructive pulmonary disease (COPD), bronchiectasis, and cystic fibrosis to prevent exacerbations, reduce hospitalizations, and improve quality of life. In clinical studies, the system has demonstrated superior sputum clearance and improved user comfort compared to conventional airway clearance devices.

“Synchrony’s vision is to fundamentally change how chronic lung disease is treated at home,” said Anat Shani, CEO of Synchrony Medical. “With the backing of strong partners like Edge Medical and the NJIEF, we have established our U.S. headquarters in New Jersey, home to one of the most dynamic health innovation ecosystems in the country. This additional funding accelerates our ability to scale U.S. commercial activity and expand patient access to LibAirty™ nationwide, while continuing to innovate.”

NJIEF is a public-private partnership under the New Jersey Economic Development Authority (NJEDA), designed to attract, anchor, and scale high-potential companies building and commercializing innovative technologies in New Jersey. The new funding matches an investment by NJIEF Qualified Venture Fund partner Edge Medical Ventures, a medtech venture fund and studio that develops and invests in breakthrough medical technologies with strong clinical validation and global market potential.

“Synchrony’s LibAirty system combines both strong clinical validation and real-world usability, serving as a successful proof-of-concept for our co-investment model with NJEDA,” said Shai Policker, Managing Partner at Edge Medical Ventures. “We are already seeing clear signs of commercial traction and believe Synchrony is well positioned to lead the airway clearance market.”

About Synchrony Medical

Synchrony Medical is a commercial-stage respiratory care technology company developing advanced at-home airway clearance solutions. The company’s FDA-cleared LibAirty™ Airway Clearance system was developed in collaboration with leading pulmonologists at the Sheba Medical Center, inspired by proven airway clearance techniques. LibAirty transforms respiratory therapy into an easy-to-manage daily routine that patients can perform independently at home, setting a new standard of care for people living with chronic lung disease. Founded at the MEDX Xelerator venture studio supported by the Israeli Innovation Authority, Synchrony Medical is headquartered in Jersey City, New Jersey, with additional operations in Or Yehuda, Israel. For more information, visit https://libairty.health/.

Media Contact:

Aviva Sapir
Number 10 Strategies
[email protected]

SOURCE Synchrony Medical

• Este avance aborda un desafío antiguo en la medicina genética con el objetivo de desarrollar una nueva generación de terapias celulares y génicas curativas.
• Desarrollado en colaboración con NVIDIA mediante el entrenamiento de los modelos de IA evolutiva más grandes en un nuevo conjunto de datos recopilados globalmente, acelerado por NVIDIA BioNeMo.
• El mismo modelo versátil también ayudó a diseñar nuevas moléculas de péptidos antimicrobianos con una tasa de éxito confirmada en laboratorio del 97 %, incluyendo candidatos que demostraron ser altamente eficaces contra superbacterias resistentes a múltiples fármacos.
• Basecamp Research también incorpora a NVentures como inversor antes de la ronda de financiación de Serie C tras una sólida colaboración técnica en los modelos EDEN.

LONDRES y CAMBRIDGE, Mass. , 12 de enero de 2026 — Basecamp Research, un laboratorio de IA de vanguardia que aprovecha la evolución para diseñar nuevos medicamentos, anunció hoy los primeros modelos de IA capaces de insertar genes programables, lo que ofrece una nueva forma de reemplazar genes defectuosos y reprogramar células para uso terapéutico. Desarrollados en colaboración con NVIDIA, estos modelos impulsan el desarrollo de una nueva generación de tratamientos para el cáncer y las enfermedades hereditarias. Paralelamente, Basecamp Research consiguió una inversión de NVentures (la división de capital de riesgo de NVIDIA) en su ronda previa a la Serie C, tras años de estrecha colaboración técnica, lo que ayudará a la compañía a acelerar sus esfuerzos de investigación y desarrollo.

“Creemos que estamos en el inicio de una importante expansión de las posibilidades para los pacientes con cáncer y enfermedades genéticas“, declaró John Finn, director científico de Basecamp Research. “Al utilizar la IA para diseñar la enzima terapéutica, esperamos acelerar el desarrollo de curas para miles de enfermedades intratables, transformando potencialmente millones de vidas”.

Inserción génica programable

La inserción génica programable (colocar grandes secuencias terapéuticas de ADN en puntos precisos del genoma humano) ha sido un objetivo central de la medicina genética durante décadas. Los enfoques actuales basados en CRISPR solo pueden realizar pequeñas modificaciones y, para ello, deben dañar el ADN, lo que limita su uso. Basecamp Research es la primera en demostrar que la IA puede diseñar enzimas capaces de realizar grandes inserciones génicas en puntos definidos del genoma humano, abriendo así un camino largamente buscado hacia las terapias programables.

La plataforma de inserción genética programable por IA (aiPGI™) de Basecamp Research está impulsada por EDEN, una nueva familia de modelos de IA evolutiva desarrollados con NVIDIA y entrenados en BaseData™, el conjunto de datos genómicos patentado de la compañía, el más grande de su tipo. Los modelos aprenden el lenguaje del ADN y los patrones de evolución, lo que permite a los algoritmos diseñar nuevas terapias programables para el cáncer y las enfermedades genéticas.

En resultados de laboratorio publicados hoy en un artículo coescrito por NVIDIA, Microsoft y destacados académicos [enlace], los modelos EDEN diseñaron múltiples proteínas de inserción activas para el 100 % de los sitios diana relevantes para enfermedades en el genoma humano. Requerían únicamente el sitio diana genómico como indicador, lo que representa un avance significativo en la capacidad de los modelos de IA.

Basecamp Research ya ha demostrado la inserción en más de 10.000 ubicaciones relacionadas con enfermedades en el genoma humano, incluyendo la integración terapéuticamente relevante de ADN que combate el cáncer en células T humanas primarias en nuevos sitios de refugio seguro. Esto produjo células CAR-T que muestran una potente destrucción de células cancerosas, con una eliminación de células tumorales superior al 90 % en ensayos de laboratorio.

Moléculas diseñadas con IA para combatir las “superbacterias”

En otra tarea clave de diseño terapéutico de vanguardia, dirigida a la crisis mundial de farmacorresistencia, el mismo modelo demostró su versatilidad al diseñar una biblioteca específica de nuevos péptidos antimicrobianos (AMP), pequeñas proteínas con el potencial de eliminar bacterias dañinas, con el 97 % de los candidatos demostrando actividad confirmada en pruebas de laboratorio. En colaboración con científicos de la Universidad de Pensilvania, dirigidos por el profesor César de la Fuente, los AMP de mayor rendimiento mostraron una alta potencia contra patógenos de prioridad crítica y multirresistentes, ofreciendo una nueva y poderosa herramienta en la lucha contra las peligrosas “superbacterias”.

Avance impulsado por datos únicos y modelos de IA de vanguardia

Los modelos EDEN que impulsan aiPGI™ se entrenaron con más de 10 billones de tokens de ADN evolutivo de más de un millón de especies recién descubiertas. Estos datos se recopilaron durante cinco años en más de 150 ubicaciones en 28 países y cinco continentes como parte de una novedosa estrategia de recopilación de datos impulsada por la empresa, publicados en junio de 2025.

El modelo EDEN más grande se entrenó con 1,95 x 10²⁴ FLOPS de cómputo en un clúster de 1.008 NVIDIA Hopper GPUs y se aceleró con bibliotecas de NVIDIA BioNeMo, lo que lo hace comparable en escala a los modelos de clase GPT-4 y lo sitúa entre los modelos biológicos con mayor intensidad computacional jamás reportados.

Activos terapéuticos en desarrollo

Estas capacidades respaldan la nueva línea de productos de Basecamp Research en terapias celulares y génicas, abriendo el camino a tratamientos más precisos, predecibles y personalizados que los disponibles actualmente. El objetivo de la compañía es desarrollar terapias potencialmente curativas para diversas indicaciones de cáncer y enfermedades genéticas, impulsadas por las mejoras continuas de BaseData™, los modelos EDEN y aiPGI^™.

Acerca de Basecamp Research
Basecamp Research se dedica a resolver los principales desafíos de las ciencias de la vida explorando Beyond Known Biology™. La empresa crea modelos de IA de vanguardia utilizando BaseData, el conjunto de datos biológicos más grande del mundo, de origen ético y representativo a nivel mundial. Basecamp Research recopila y selecciona sus propios datos biológicos mediante colaboraciones con más de 152 organizaciones en 28 países, lo que permite a su IA acceder a una diversidad genética inexistente para los modelos entrenados en bases de datos públicas. Esto permite a Basecamp Research diseñar nuevas secuencias de proteínas y sistemas biológicos que pueden acelerar la investigación y el desarrollo terapéutico.

Basecamp Research colabora con empresas biofarmacéuticas e instituciones académicas de todo el mundo, y su trabajo ha sido reconocido con distinciones como la lista de las 10 empresas más innovadoras en biotecnología de Fast Company y la lista Sifted AI100, respaldada por FT, de las principales empresas emergentes de IA de Europa. Más información en basecamp-research.com.

BaseData^™, Beyond Known Biology^™, EDEN-GLM^™ y aiPGI^™ son marcas y tecnologías de Basecamp Research.